56 results on '"Illmer, Thomas"'
Search Results
2. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
3. Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
4. Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
5. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
6. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
7. Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group
8. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
9. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
10. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
11. Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
12. Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial
13. Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
14. Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)
15. Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
16. Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)
17. Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial
18. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial
19. CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
20. Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial
21. Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update
22. Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
23. Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction
24. Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial
25. Functional Influence of CXCL12 Regulating miRNAs in Mesenchymal Stem Cells (MSCs).
26. Expression of the Nuclear Corepressor Ski Predicts Response to Histone Deacetylase Inhibitor Valproic Acid in Cells of Acute Myeloid Leukemia.
27. Regulatory Potential of miRNAs on CXCL12 Expression in Human Mesenchymal Stem Cells (MSC)
28. High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia
29. MicroRNA29a regulates the expression of the nuclear oncogene Ski
30. Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL
31. Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy.
32. miRNA29a Regulates Oncogenic SKI Expression in Acute Myeloid Leukemia (AML).
33. Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial
34. MicroRNA Mir-23a Regulates SDF-1alpha Expression in Human Bone Marrow-Derived Mesenchymal Stem Cells
35. Comprehensive Risk Factor Analysis in 939 Adults with Acute Myeloid Leukemia Receiving Risk Stratified Post-Remission Therapy: Results of the Prospective Randomized AML96 Trial of the German Study Initiative Leukemia (DSIL).
36. Insertion and Deletions Mutations of the CEBPA Gene Affecting the bZIP Region Are Strong Predictors for Achieving Complete Remission and Improved Overall Survival in Adult Patients with AML - An Analysis in 1536 Patients Treated in the AML96 Protocol of the DSIL.
37. Detection of Herpesvirus and Adenovirus Infections in Patients Undergoing Stem Cell Transplantation: Looking Below the Tip of the Iceberg with the Microarray Technology.
38. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Results of a Phase I/II Trial.
39. Elderly Patients with Acute Myeloid Leukemia Are Not All the Same: Results of the Prospective DSIL AML96 Trial.
40. Early Treatment Intensification in High Risk (HR)-AML Patients Using Allogeneic Hematopoietic Stem Cell Transplantion in a Randomized Multicenter Setting.
41. MiRNA Expression Signatures in Acute Myeloid Leukemia Are Predictors for Patient Outcome.
42. Inhibition of PDGFRβ by Imatinib Mesylate Suppresses Proliferation and Alters Differentiation of Human Mesenchymal Stem Cells In Vitro.
43. DNA-Microarray for Simultaneous Detection of Herpesviruses and Adenovirus in Patients Undergoing Allogeneic Stem Cell Transplantation.
44. Hematopoietic Progenitor Cells Harbouring BCR-ABL Exhibit Increased Adhesiveness but an Impaired Migration and Homing Potential.
45. Comparison of Different Techniques for the Detection of FLT3-Mutations in Exons 14/15 and 20 in Patients with Acute Myeloid Leukemia.
46. Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.
47. The Role of Expression of FLICE and FLICE-Inhibitory Protein Isoforms in Acute Myeloid Leukemia.
48. Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation.
49. AF1q Is a Novel Poor Prognostic Marker for Adult Acute Myelogenous Leukemia (AML) Patients with Normal Cytogenetics.
50. Gemtuzumab Ozogamicin (Mylotarg®) as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.